Phase I study on bruceantin administered on a weekly schedule
Liesmann, J.; Belt, R.J.; Haas, C.D.; Hoogstraten, B.
Cancer Treatment Reports 65(9-10): 883-885
1981
ISSN/ISBN: 0361-5960 PMID: 7273023 Document Number: 171487
Fifteen adult patients with advanced solid tumors received bruceantin at doses of 1.6-6.0 mg/m2 i.v. for 30 min/wk .times. 4, followed by a 2 wk rest. The dose-limiting toxic effect was nausea and vomiting, which was more severe in patients with hepatic metastases or liver function abnormalities. Other sporadic toxic effects included fever, chills, malaise, alopecia, hypotension, thrombocytosis and leukocytosis. Hematologic toxicity was insignificant. The recommended starting dose for phase II studies is 5 mg/m2 per wk .times. 4, every 6 wk, with a reduction to 3 mg/m2 for patients with hepatic metastases.